Imara M&A

Merger with Imara Has the Potential to be Transformative for Enliven Transition into a clinical-stage, precision oncology company with multiple shots on goal imara Enliven THERAPEUTICS Enliven Therapeutics opportunity Provides Imara shareholders with opportunity to participate in the Enliven growth story, at a pivotal time for Enliven Diversified and clinical-stage portfolio Two parallel lead programs currently in development, ELVN-001, a highly selective BCR-ABL inhibitor for Chronic Myeloid Leukemia, and ELVN-002, a highly selective HER2 and pan-HER2 mutant irreversible inhibitor for HER2-driven cancers, as well as additional programs in the research pipeline Multiple near-term milestones Planned steady stream of company milestones, including early Phase 1 data for ELVN-001 expected by the end of 2023 Strong balance sheet supports runway into 2026 Combined company expected to have approximately $300 million in cash and cash equivalents upon closing; resources expected to fund operations into early 2026 3

View entire presentation